{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:47:46Z","timestamp":1770079666206,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ctro.2025.101093","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T23:29:03Z","timestamp":1765063743000},"page":"101093","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Benefit of prophylactic pelvic irradiation in intermediate-risk prostate cancer: A multicenter retrospective study (iPPAPI)"],"prefix":"10.1016","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0526-8632","authenticated-orcid":false,"given":"Charles","family":"Raynaud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafik","family":"Nebbache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazid","family":"Belkacemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrus","family":"Chargari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Durdux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Quero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Emmanuel","family":"Bibault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2025.101093_b0005","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","article-title":"Recent patterns and trends in global prostate cancer incidence and mortality: an update","volume":"87","author":"Schafer","year":"2025","journal-title":"Eur Urol"},{"issue":"46","key":"10.1016\/j.ctro.2025.101093_b0010","first-page":"3040","article-title":"Prostate cancer incidence and mortality trends in 37 European countries: an overview","volume":"2010","author":"Bray","year":"1990","journal-title":"Eur J Cancer Oxf Engl"},{"key":"10.1016\/j.ctro.2025.101093_b0015","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate cancer: a review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ctro.2025.101093_b0020","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1056\/NEJMcp2209151","article-title":"Screening for prostate cancer","volume":"388","author":"Pinsky","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctro.2025.101093_b0025","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ctro.2025.101093_b0030","article-title":"NCCN guidelines index table of contents discussion","author":"Spratt","year":"2025","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.ctro.2025.101093_b0035","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ijrobp.2016.06.2455","article-title":"Is there a role for pelvic irradiation in localized prostate adenocarcinoma? update of the long-term survival results of the GETUG-01 randomized study","volume":"96","author":"Pommier","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2025.101093_b0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0360-3016(94)90138-4","article-title":"Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and gleason score in men with clinically localized prostate cancer","volume":"28","author":"Roach","year":"1994","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.101093_b0045","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctro.2025.101093_b0050","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase III randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2025.101093_b0055","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/apm.12533","article-title":"International Society of Urological Pathology (ISUP) grading of prostate cancer \u2013 an ISUP consensus on contemporary grading","volume":"124","author":"Egevad","year":"2016","journal-title":"APMIS"},{"key":"10.1016\/j.ctro.2025.101093_b0060","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) n.d."},{"key":"10.1016\/j.ctro.2025.101093_b0065","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) 2017."},{"key":"10.1016\/j.ctro.2025.101093_b0070","unstructured":"etctn-ctcae-v4-03-to-ctcae-v5-ctep-aers-user-guide.pdf n.d."},{"key":"10.1016\/j.ctro.2025.101093_b0075","first-page":"1445","article-title":"Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer","volume":"277","author":"Partin","year":"1997","journal-title":"A Multi-Institutional Update JAMA"},{"key":"10.1016\/j.ctro.2025.101093_b0080","doi-asserted-by":"crossref","first-page":"S257","DOI":"10.21037\/tau.2019.04.01","article-title":"Long term results of the NRG\/RTOG 9413: a key study but one of the most confusing study in prostate cancer radiotherapy!","volume":"8","author":"Pommier","year":"2019","journal-title":"Transl Androl Urol"},{"key":"10.1016\/j.ctro.2025.101093_b0085","doi-asserted-by":"crossref","first-page":"5366","DOI":"10.1200\/JCO.2006.10.5171","article-title":"Is there a role for pelvic irradiation in localized prostate adenocarcinoma? preliminary results of GETUG-01","volume":"25","author":"Pommier","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2025.101093_b0090","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ijrobp.2008.07.053","article-title":"Predicting the risk of pelvic node involvement among men with prostate cancer in the contemporary era","volume":"74","author":"Nguyen","year":"2009","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.101093_b0095","unstructured":"Urofrance | Recommandations du comit\u00e9 de canc\u00e9rologie de l\u2019Association Fran\u00e7aise d\u2019Urologie - actualisation 2022-2024\u00a0: cancer de la prostate - diagnostic et prise en charge de la maladie localis\u00e9e - Urofrance n.d. https:\/\/www.urofrance.org\/recommandation\/recommandations-du-comite-de-cancerologie-de-lassociation-francaise-durologie-actualisation-2022-2024-cancer-de-la-prostate-diagnostic-et-prise-en-charge-de-la-maladie-localise\/?date=&themes=1342&search=# (accessed August 22, 2025)."},{"key":"10.1016\/j.ctro.2025.101093_b0100","first-page":"329","article-title":"External radiotherapy for prostatic cancers","volume":"26","author":"de Crevoisier","year":"2022","journal-title":"Cancer Radiother J Soc Francaise Radiother Oncol"},{"key":"10.1016\/j.ctro.2025.101093_b0105","unstructured":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025_updated.pdf n.d."},{"key":"10.1016\/j.ctro.2025.101093_b0110","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"D\u2019Amico","year":"1998","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.ctro.2025.101093_b0115","article-title":"Interventions to reduce acute and late adverse gastrointestinal effects of pelvic radiotherapy for primary pelvic cancers","volume":"1","author":"Lawrie","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctro.2025.101093_b0120","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.semradonc.2025.04.010","article-title":"Elective regional nodal irradiation in prostate cancer","volume":"35","author":"Chilukuri","year":"2025","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.101093_b0125","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ijrobp.2018.10.003","article-title":"Toxicity and patient-reported outcomes of a phase 2 randomized trial of prostate and pelvic lymph node versus prostate only radiotherapy in advanced localised prostate cancer (PIVOTAL)","volume":"103","author":"Dearnaley","year":"2019","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.101093_b0130","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.urology.2023.05.012","article-title":"The long-term incidence and quality of life outcomes associated with treatment-related toxicities of external beam radiotherapy for prostate cancer","volume":"178","author":"Lonergan","year":"2023","journal-title":"Urology"},{"key":"10.1016\/j.ctro.2025.101093_b0135","doi-asserted-by":"crossref","first-page":"14828","DOI":"10.1002\/jcp.28283","article-title":"A systematic review of radiation\u2010induced testicular toxicities following radiotherapy for prostate cancer","volume":"234","author":"Farhood","year":"2019","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ctro.2025.101093_b0140","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/bjc.2015.275","article-title":"Patient-reported sexual toxicity after radiation therapy in long-term prostate cancer survivors","volume":"113","author":"Olsson","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctro.2025.101093_b0145","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1002\/cncr.32288","article-title":"Patient\u2010reported sexual quality of life after different types of radical prostatectomy and radiotherapy: analysis of a population\u2010based prospective cohort","volume":"125","author":"Mullins","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.ctro.2025.101093_b0150","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41443-020-00389-1","article-title":"Sexual function and rehabilitation after radiation therapy for prostate cancer: a review","volume":"33","author":"Nguyen","year":"2021","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.ctro.2025.101093_b0155","first-page":"395","article-title":"Barriers to sexual recovery in men with prostate, bladder and colorectal cancer","volume":"40","author":"Zhu","year":"2022","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.ctro.2025.101093_b0160","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.ijrobp.2021.01.034","article-title":"Underascertainment of clinically meaningful symptoms during prostate cancer radiation therapy\u2014does this vary by patient characteristics?","volume":"110","author":"Sud","year":"2021","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.101093_b0165","unstructured":"Radiation Therapy Oncology Group. Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial. clinicaltrials.gov; 2024."},{"key":"10.1016\/j.ctro.2025.101093_b0170","first-page":"22","article-title":"PIVOTALboost: a phase III randomised controlled trial of prostate and pelvis versus prostate alone radiotherapy with or without prostate boost (CRUK\/16\/018)","volume":"25","author":"Syndikus","year":"2020","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.ctro.2025.101093_b0175","doi-asserted-by":"crossref","first-page":"S673","DOI":"10.1016\/j.annonc.2021.08.1159","article-title":"646TiP a randomized phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse: the PEACE 2 trial from Unicancer","volume":"32","author":"Blanchard","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctro.2025.101093_b0180","first-page":"1","article-title":"Role of multi\u2011omics in advancing the understanding and treatment of prostate cancer (Review)","volume":"31","author":"Yan","year":"2025","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.ctro.2025.101093_b0185","doi-asserted-by":"crossref","first-page":"7475","DOI":"10.3390\/ijms26157475","article-title":"Omics-mediated treatment for advanced prostate cancer: moving towards precision oncology","volume":"26","author":"Fatima","year":"2025","journal-title":"Int J Mol Sci"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630825001855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630825001855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:21:23Z","timestamp":1770034883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630825001855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":37,"alternative-id":["S2405630825001855"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2025.101093","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Benefit of prophylactic pelvic irradiation in intermediate-risk prostate cancer: A multicenter retrospective study (iPPAPI)","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2025.101093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101093"}}